Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences executive Keeley M. Cain Wettan, EVP Gen Counsel, Legal & Comp, filed an initial ownership report showing direct holdings in Gilead Sciences, Inc. common stock and equity awards as of February 4, 2026. The filing lists 3,944 shares of common stock, restricted stock units covering 5,440 and 11,342 shares, and several non-qualified stock options with exercise prices from $57.92 to $117.21 and expirations between 2032 and 2035. The restricted stock units and options vest over three- or four-year schedules, with portions vesting on the first anniversary of grant and the remainder vesting quarterly or annually until fully vested.
Gilead Sciences reported higher fourth quarter and full-year 2025 results, driven mainly by its HIV and liver disease portfolios. Q4 2025 revenue rose 5% to $7.9 billion, and diluted EPS increased to $1.74. Full-year 2025 revenue grew 2% to $29.4 billion, with diluted EPS jumping to $6.78 from $0.38, helped by lower IPR&D charges, higher product sales and lower SG&A.
Product sales excluding Veklury increased 4% to $28.0 billion in 2025. HIV sales grew 6% to $20.8 billion, including Biktarvy up 7% to $14.3 billion and Descovy up 31% to $2.8 billion. Liver disease sales rose 6% to $3.2 billion, while Veklury declined 49% to $911 million as COVID-19 hospitalizations fell.
Non-GAAP diluted EPS for 2025 was $8.15, up from $4.62, reflecting strong underlying profitability. Gilead generated $10.0 billion in operating cash flow during 2025, maintained product gross margin near 78% on a GAAP basis and 86% on a non-GAAP basis, and ended the year with $10.6 billion in cash, cash equivalents and marketable debt securities.
For full-year 2026, Gilead projects product sales of $29.6–$30.0 billion, including Veklury of $600 million, and diluted EPS of $6.75–$7.15, with non-GAAP diluted EPS of $8.45–$8.85. The company highlighted continued launches such as Yeztugo for HIV prevention and Livdelzi for liver disease, as well as planned oncology and HIV pipeline launches.
Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares. On February 5, 2026, he exercised 115,640 non-qualified stock options at a price of $66.01 per share and received the same number of common shares.
That same day, he sold 115,640 shares of Gilead common stock at $150 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly owned 613,912 shares of Gilead common stock.
Gilead Sciences officer Johanna Mercier, Chief Commercial & Corporate Affairs Officer, reported performance-based stock awards on common shares. On February 3, 2026, she acquired 44,867 shares at $0 following certification that performance goals were met for awards granted in March 2023 and March 2024.
On the same date, 24,800 shares were withheld at $143.28 per share, likely for tax obligations, leaving her with 123,288 shares of Gilead common stock held directly. Portions of the 2024 award will be issued only after additional service requirements are satisfied.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock. On February 3, 2026, he acquired 44,867 shares of common stock at $0 per share, tied to performance share awards granted on March 10, 2023 and March 10, 2024.
These awards vested after the Compensation and Talent Committee certified achievement of performance goals, though shares from the March 10, 2024 grant will only be issued once additional service requirements are met. On the same date, he had a disposition coded "F" of 24,802 shares at $143.28 per share. Following these transactions, Dickinson directly owns 170,568 shares of Gilead common stock.
Gilead Sciences Chairman and CEO Daniel P. O'Day reported equity compensation activity involving the company’s common stock. On February 3, 2026, he acquired 131,675 shares at $0 under performance share awards granted in March 2023 and March 2024 after performance goals were certified.
On the same date, 74,461 shares were disposed of at $143.28, typically reflecting shares withheld to cover taxes on the vesting. After these transactions, O'Day directly owned 613,912 shares of Gilead common stock. Portions of the 2024 performance award will only be issued once additional service-vesting requirements are met.
Daniel O'Day filed to sell 115640 shares of Gilead common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 17346000.00 and 1240679623 Gilead shares outstanding.
The 115640 shares were acquired on 02/05/2026 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, O'Day sold additional Gilead common shares in four trades totaling 145640 shares for gross proceeds of 187627,? wait.
FMR LLC has disclosed a significant ownership stake in Gilead Sciences Inc. As of 12/31/2025, FMR LLC reported beneficial ownership of 65,539,476.75 shares of Gilead common stock, representing 5.3% of the outstanding class.
FMR LLC has sole voting power over 57,299,411.36 shares and sole dispositive power over 65,539,476.75 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with beneficial ownership of the same 65,539,476.75 shares and 5.3% of the class.
The filing states that the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of Gilead Sciences Inc., other than activities solely in connection with a nomination under Rule 240.14a-11.
Gilead Sciences Chairman & CEO Daniel O'Day reported planned share sales. On 01/28/2026, he sold 5,032 shares of common stock at a weighted average price of $139.5441 and 4,968 shares at $140.2426 in open-market transactions.
These sales were made under a Rule 10b5-1 trading plan adopted on February 28, 2025. After the transactions, O'Day directly owned 556,698 Gilead shares. The first group of sales occurred at prices ranging from $138.99 to $139.97, and the second from $140.00 to $140.57.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
